Both ARP-sEVs and CDP-sEVs could effectively deliver p53 and significantly inhibit the proliferation and induce apoptosis of H1299 lung cancer cells, with ARP-sEVs demonstrating notably superior anti-tumor properties than CDP-sEVs. This evidence concerns the gene TP53 and lung carcinoma.